Goldman Sachs’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-7,200
Closed -$296K 6504
2021
Q3
$296K Hold
7,200
﹤0.01% 5507
2021
Q2
$408K Buy
+7,200
New +$266K ﹤0.01% 5331
2021
Q1
Sell
-5,000
Closed -$351K 6130
2020
Q4
$351K Buy
+5,000
New +$205K ﹤0.01% 4811
2017
Q4
Sell
-40,000
Closed -$960K 6409
2017
Q3
$960K Buy
40,000
+4,000
+11% +$76.1K ﹤0.01% 4606
2017
Q2
$604K Buy
+36,000
New +$649K ﹤0.01% 4935

Other funds holding EDIT

Goldman Sachs's EDIT Position: Q1 2026 in Review

Goldman Sachs reduced its Editas Medicine (EDIT) stake by 37% in Q1 2026, selling an estimated $684K and leaving 558,577 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4859.

Goldman Sachs first reported a position in EDIT in Q1 2016 and has held it in 41 quarters since. The position peaked at $71.8M in Q4 2020. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Goldman Sachs held 558,577 shares of Editas Medicine worth $1.38M as of Q1 2026.
  • Goldman Sachs sold 323,383 Editas Medicine shares in Q1 2026, an estimated $684K.
  • Editas Medicine made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4859 holding.
  • Goldman Sachs first reported a position in Editas Medicine in Q1 2016 and has held it in 41 quarters since.
  • Goldman Sachs's Editas Medicine position peaked at $71.8M in Q4 2020.
  • 208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.